Results 251 to 260 of about 362,523 (334)

Cardenolide‐Engineered Extracellular Vesicles Augment Drug Uptake and Cytotoxicity in Non‐small Cell Lung Cancer Cells

Small Methods, EarlyView.
Cardenolide‐functionalized extracellular vesicles enable targeted delivery of the chemotherapeutic doxorubicin to A549 lung cancer cells by binding Na+/K+‐ATPase, which is overexpressed in these cells. Surface‐modified, drug‐loaded EVs exhibit enhanced cytotoxicity compared to unmodified EVs and free drug, suggesting this system may lower the effective
Maja Dorfner, Anika Mifka, Rodrigo Maia de Pádua, Izabella Thaís da Silva, Iara Zanella Guterres, Lorenzo Sana, Gregor Fuhrmann, Jennifer Munkert   +7 more
wiley   +1 more source

An updated review on systemic therapy for brain metastases in non-small cell lung cancer. [PDF]

Transl Cancer Res
Louis S, Aboubechara JP, Saigal K, Cao T, Nagpal S.   +4 more
europepmc   +1 more source

Microfluidic single‐cell technologies for immunotherapeutic target discovery: From design concepts to preclinical applications

VIEW, EarlyView.
Immunotherapy leverages the immune system to treat cancer and autoimmune diseases but is hindered by cellular heterogeneity in tissues and immune landscapes. Single‐cell technologies, particularly microfluidic‐enabled omics, revolutionize disease understanding by resolving this complexity at unprecedented resolution.
Haopu Wang, Kangfu Chen, Zongjie Wang
wiley   +1 more source

Mechanistic insights into DEHP-induced progression of non-small cell lung cancer based on network toxicology and molecular docking. [PDF]

Sci Rep
Chen Z, Wang C, Li Y, Xiao X, Zhao H, He B, Bai H, Zhao R, Zhang G, Feng J.   +9 more
europepmc   +1 more source

Relapsed NSCLC

Oncology Times, 2004
openaire   +2 more sources

Tumour‐informed workflow to use ctDNA as a biomarker for risk of recurrence in head and neck cancer patients post‐treatment

VIEW, EarlyView.
Our study presents a tumour‐informed circulating tumour DNA (ctDNA) workflow designed to enhance the detection of recurrence in head and neck cancer patients, addressing key challenges such as low ctDNA tumour fractions and tumour heterogeneity. Abstract Circulating tumour DNA (ctDNA) is a promising minimally invasive biomarker for monitoring treatment
Xiaomin Huang, Paul Leo, Mhairi Clout, Lynn Fink, Jonathan Ellis, Brett G. M. Hughes, Lizbeth Kenny, Sarju Vasani, Chamindie Punyadeera   +8 more
wiley   +1 more source

<p>Immunotherapy after EGFR‑TKI treatment in advanced non‑small cell lung cancer: Current status and future perspectives (Review)</p>. [PDF]

Oncol Rep
Ma H, Li L, Jiao C, Cheng Y, He J, Jiang C, Tong Q, Yi D, Zhang Y.   +8 more
europepmc   +1 more source

Plasma Proteomics Analysis Identifying IGFBP2 as a Potential Diagnostic Biomarker for Laryngeal Squamous Cell Carcinoma

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective Currently, there are no blood biomarkers available for the early diagnosis of laryngeal squamous cell carcinoma (LSCC). The objective of this study was to search for potential plasma biomarkers for the diagnosis of LSCC. Methods Plasma samples were taken from patients with LSCC and healthy controls for proteomic analysis.
Shuang Teng, Ling‐Mei Qu, Jun‐Jie Liu, Yu‐Shan Li, Zi‐Qi Chen, Shuo Liu, Zhao‐Nan Xu, Meng Jin, Qiu‐Ying Li, Qin Wu, Hong‐Tian Yi, Xian‐Ji Shen, Bing‐Rui Yan, Ya‐Nan Sun   +13 more
wiley   +1 more source

ZC3H15 regulates the ubiquitination of PTEN via recruitment of TRIM56 and promotes malignant progression of non-small cell lung cancer. [PDF]

Cell Death Dis
Wu P, Yao P, Zhao M, Cheng M.
europepmc   +1 more source

A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC

, 2019
Martin Reck, Alexander Luft, Igor Bondarenko, Serhii Shevnia, Dmytro Trukhin, Н. В. Коваленко, K Vacharadze, Freschi Andrea, A. O. Hontsa, Jeong‐Yoon Choi, D.B. Shin   +10 more
openalex   +1 more source